In my presentation, I will discuss several biomarker studies and platforms. One of them is, for instance, the endocannabinoid system that we studied. And I think the endocannabinoid system is extremely interesting because it’s also implicated in depression. And as you might know, there is a high comorbidity between migraine and depression. Also, patients who have this comorbid condition of depression are more likely to chronify...
In my presentation, I will discuss several biomarker studies and platforms. One of them is, for instance, the endocannabinoid system that we studied. And I think the endocannabinoid system is extremely interesting because it’s also implicated in depression. And as you might know, there is a high comorbidity between migraine and depression. Also, patients who have this comorbid condition of depression are more likely to chronify. I think getting more knowledge about this system might be helpful, again, to identify new treatment pathways for our patients, and also might be able to help to prevent chronicification of migraine. I think this is one of the biomarker studies which I’m extremely interested in and enthusiastic about.
Another example, which we just started, is the studies on sex hormones. As you may know, for instance, in migraine, the majority of patients are females. There are three times more females affected with migraine than males, and all these females also report to us that they consider sex hormonal changes to be very important in the propagation of migraine attacks. We do not know what kind of sex hormone levels are important in this relationship, so I think we actually need to study this more closely, not only looking at estrogen and progesterone but doing a much more thorough search into the sex hormonal studies.